To examine over-screening of older Israelis for colon and breast cancer. DESIGN: Cross sectional. SETTING: Clalit Health Services (CHS), Israel's largest health maintenance organization (HMO), provides care for more than half of the country's population and operates a national age-based programs for cancer screening. PARTICIPANTS: All community-dwelling members aged 65 to 79 in 2014 (N = 370,876). MEASUREMENTS: We used CHS data warehouse to evaluate cancer screening during 2014. Life expectancy (LE) was estimated using the validated Schonberg index. RESULTS: Almost one-quarter (23.1%; 15.6% of adults aged 65-74, 42.7% of adults aged 75-79) of the study population had an estimated LE of less than 10 years. Annual fecal occult blood test and biannual mammography rates among adults aged 65 to 74 with a LE of 10 years or longer were 37.1% and 70.0%, respectively. Rates dropped after age 75 (4.0%, 19.5%) and to a lesser extent with a LE of less than 10 years (31.6%, 56.4%). Prostate-specific antigen testing is not part of the national screening program, and the proportion of people tested (42.6%), did not vary similarly with age of 75 and older (43.2%) or LE of less than 10 years (38.1%).
W orldwide, in developed countries, the population of adults aged 65 and older is rising rapidly, and cancer incidence increases with age. Therefore, most developed countries include adults aged 65 to 74 in national screening programs for breast (women only) and colorectal cancer (CRC), but it is estimated that 1,000 older adults need to be screened to avoid one breast or colon cancer death in 10 years. 1 Because of this 10-year lag time to benefit, some organizations recommend that adults with less than 10 years of life expectancy (LE) not be screened for these cancers. [2] [3] [4] The rationale is that these people will not live long enough to experience the life-prolonging benefits of cancer screening. Instead, screening these people only puts them at risk of the harms of cancer screening, including anxiety resulting from false-positive tests, overdiagnosis (detection of tumors that are of no threat), and complications from examination for and treatment of cancer. 5 Despite this, 40% to 50% of U.S. women aged 65 and older with less than a 10-year LE undergo screening for breast cancer with mammography, and similarly 40% to 50% of U.S. adults with less than a 10-year LE undergo CRC screening. [6] [7] [8] [9] In addition, although screening for prostate cancer with a prostate specific antigen (PSA) test is controversial for any man regardless of age, many continue to be screened, including those with a short LE.
Based on recommendations from the Israeli Task Force on Health Promotion, the Israeli Ministry of Health invites women younger than 75 to undergo mammography screening and adults younger than 75 to have a fecal occult blood test (FOBT), regardless of their health status or LE. 11 A quality indicator program is in place to monitor and encourage compliance of age eligible members for the CRC and breast cancer early-detection programs. Clalit Health Services (CHS) is the largest health maintenance organization in Israel. Its active outreach programs promote participation but are stopped once the person has reached the age of 75. Electronic medical record reminders for screening are visible for doctors during every medical interaction. Primary care physicians and specialists order PSA tests for medical followup of prostate cancer, as well as for screening purposes. Neither the Ministry of Health nor CHS recommends or encourages routine prostate cancer screening. Comparing PSA use (no active outreach and not measured) with that of FOBT and mammography (active outreach and measured) according to age and LE might help to illuminate the role of outreach and quality measures in over-and underscreening of older Israelis. We are unaware of studies that have examined overuse of cancer screening in older adults outside the United States. Therefore, we aimed to examine overuse of cancer screening in older Israelis who were members of CHS.
METHODS

Data Sources
Data were accessed from the CHS data warehouse. CHS insures and provides healthcare to 52% of Israel's population (>4,300,000 beneficiaries). The CHS medical information system is comprehensive, comprising sociodemographic data; information on use of healthcare services, drug purchases, laboratory and imaging tests; and a widescale registry of chronic diagnoses. 12 The epidemiology unit of the CHS maintains a central comprehensive chronic diseases registry that is continuously updated based on an algorithm integrating all available data (hospitalization discharge diagnoses, chronic diagnoses in the primary care physician electronic medical record, laboratory test results, drug purchases, and other sources as relevant for each diagnosis). 13 
Study Population
We included all community-dwelling CHS members aged 65 to 79 in 2014 (n = 370,876). We excluded nursing home residents and people who left CHS or died during 2014 (n = 3,398) and individuals who had missing data needed to measure LE (n = 4,075). From the remaining 363,403 (199,387 female, 164,016 male), we excluded people with a history of CRC when examining use of CRC screening (n = 8,126) and people with a history of breast cancer and those that underwent breast magnetic resonance imaging when examining mammography screening (n = 14,832). We excluded people with history of prostate cancer when examining prostate cancer screening (n = 7,920). Our final sample population included 363,403 individuals overall, 184,555 for evaluating breast cancer screening, 355,277 for evaluating CRC screening, and 156,096 for evaluating prostate cancer screening (Figure 1 ).
Estimating LE
To estimate the LE of each CHS member, we used the validated Schonberg mortality index initially developed using self-reported data from the U.S. National Health Interview Survey. 14, 15 The index considers a person's age, sex, body mass index (BMI), history of lung disease, cancer, diabetes mellitus, functional status (e.g., ability to perofrm household chores), smoking status, hospitalizations, perceived health, and difficulty walking three blocks. Adults with more than a 50% risk of death within 10 years based on their health score (based on scores of ≥10) are considered to have an estimated LE of less than 10 years. 16 We used data from the CHS data warehouse to extract the information needed for the Schonberg index to estimate a person's LE. Eight of the 11 elements in the index were assessed using data extracted from the CHS warehouse: age, sex, BMI, hospitalizations, smoking status, history of COPD, diabetes mellitus, and cancer. The original Schonberg index asks people to self-report whether they have difficulty walking several blocks; we used whether a person had a positive Get up and Go test, had a Norton score of 16 or less, or needed support at home. 17, 18 The original Schonberg index asks whether a person needs help from another person to perform routine chores; we used whether a person required elderly nursing or reported a limitation in instrumental activities of daily living or activities of daily living. Finally, the Schonberg index asks people whether, in general, their health is excellent, very good, good, fair, or poor; we do not have these data in the CHS warehouse, but worried that omitting this element could lead us to overestimate LE, we replaced self-rated overall health with the Charlson score, which has been shown to correlate with perceived health. 19 We mapped Chalrson scores as follows. Individuals with no comorbidities were defined as having excellent or very good self-reported health, Charlson scores of 1 were treated as having good health, and Charlson scores of 2 or greater were treated as fair or poor perceived health. As a sensitivity analysis, we repeated the calculations using a partial model without this domain. Results were similar to those of the full analysis, and thus we chose to include the full version of the index in our final report. A threshold of a modified Schonberg score of 10 was used to estimate people with a LE of less than 10 years.
Evaluation of Screening
CHS measures more then 60 quality indicators (QIs) in the domains of preventive medicine, follow-up, and outcomes of chronic diseases, including CRC and breast cancer. These are regularly captured using automated algorithms from the CHS database and were previously used to assess screening practices using laboratory test results (FOBT) or billing code claims (e.g., mammography, colonoscopy). FOBT for CRC screening and mammography for breast cancer screening are routinely offered through an ongoing active outreach program to all CHS members, in accordance with national health recommendations. All FOBT samples are analyzed in one central laboratory and recorded in the person's electronic health record. People were considered to have undergone FOBT screening for CRC if a test result was recorded in 2014 in a person without a diagnosis of CRC. Women who had undergone a mammogram in 2013 to 2014 and did not have a previous diagnosis of breast cancer were considered to have been screened. For prostate cancer, we examined whether a man had a PSA test in 2014..
Statistical Analyses
The modified Schonberg score was divided into two categories according to a threshold of 10 to identify people with a LE of less than 10 years. Chi-square tests were used to compare proportions of sample characteristics (e.g., sex, age, obesity, smoking) between patients with LE of more than 10 years and those with LE of less than 10 years. These tests were also performed to examine receipt of screening for three types of cancer according to age and LE. SPSS for Windows version 20.0 (IBM Corp., Armonk, NY) was used for analyses.
RESULTS
Of the 363,403 adults in our study population, 23.1% had an estimated LE of less than 10 years; of the 262,152 adults aged 65 to 74, 15.6% had an estimated LE of less than 10 years; and of the 101,251 adults aged 75 to 79, 42.7% had an estimated LE of less than 10 years. Table 1 demonstrates the distribution of the different health conditions that make up the Schonberg index according to LE.
The proportions of people screened for different cancer types within age and LE groups are shown in Table 2 ; 27.3% of the population underwent FOBT screening-30.2% of those with a LE of 10 years or longer and 17.3% of those with a LE of less than 10 years. For ageeligible adults aged 65 to 74, differences in screening rates were smaller (37.1% for LE ≥10 years, 31.6% for LE <10 years; P < .001). Screening rates were lower for those aged 75 to 79 (4.0% for LE ≥10 years, 3.6% for LE <10 years; P = .002), who were no longer actively invited for screening. A similar trend in the variation in mammography screening rates accoridng to age and LE was also observed. Overall, 41% of men aged 65 to 79 underwent PSA screening, and there were no meaningful differences according to age (P < .001). Smaller proportions of people with a shorter LE (38.3%) were screened than of those with a LE of 10 years of longer (42.7%) (P < .001). Figure 2 illustrates the age and LE distributions for each screening test. Smaller proportions of people with shorter LE were screened in all age groups, but differences were small. FOBT and mammography rates in people aged 75 and older were generally much lower than in younger people, a trend that was not observed in PSA tests.
DISCUSSION
We performed a cross-sectional study of all communitydwelling members of the largest health maintenance had a limited LE (<10 years). Guidelines recommend avoidance of colon, breast, or prostate cancer screening in adults with a LE of less than 10 years, but the proportions of the individuals screened did not vary meaningfully across the different LE groups. Beyond age 75, screening participation for both LE groups was much lower and was very similar for those with a LE of less than 10 years and of 10 years and longer. Of these older individuals, 57.3% had an estimated LE of 10 years and longer, but only a small fraction of them were screened. There was little difference in the high proportions of men tested for PSA regardless of age or LE status. Our results, therefore, suggest significant overscreening of older adults with short LEs and underscreening of those with longer LEs. Our data highlight how a national referral and quality measure system influences receipt of cancer screening tests in older adults. A drastic decline in rates was demonstrated for those aged 75 and older, who are not actively invited to be screened, from 36.3% to 3.8% for FOBT and from 69.5% to 18.2% for mammography. On the other hand, PSA testing rates are similar before (41.4%) and after (40.1%) age 75 in Israel. PSA screening, unlike mammography and FOBT, is not part of the national referral and quality measure system, so other factors influence its use. The fact that PSA rates are similar before and after age 75 and similar for those with LEs of less than 10 years and 10 years and longer suggests that these other factors are not driving the substantially lower rates of screening for FOBT and mammography that we observed in people aged 75 and older. Therefore, it is likely that the fact that the national screening program ends at the age of 75 mainly explains the lower rates of CRC and breast cancer screening.
Our findings are in line with those of previous studies that assessed cancer screening in people with different LEs in the United States. To the best of our knowledge similar assessments of populations outside the United States have not been reported. A previous study found that 55.7% of noninstitutionalized U.S. adults with a LE of less than 10 years had undergone CRC screening, compared with 60.8% with a LE of 10 years or longer. 6 Another study Combined, these data suggest that nonindividualized quality measures have the potential to encourage use of inappropriate care.
Israel's screening program is an organized, populationbased program, like in most other western countries and in some organizations in the United States (Kaiser Permanente Northern California, Veterans Health Administration). As such, it involves inviting the target population to participate in screening and ensuring follow-up of those with a positive screen. The CHS program provides no financial incentive to medical staff. In contrast, opportunistic screening is delivered usually through fee-for-service reimbursement of physicians, such as in most parts of the United States. Because organized screening focuses on quality assurance, the goal is to provide greater protection against the possible harms of screening, including overscreening and underscreening, poor quality, inappropriate use of resources, complications arising from screening, and poor follow-up of those with a positive screen. 21 A morepersonalized approach within this organized system, such as adding predicted LE to the inclusion criteria, may help minimaize those harms.
The use of the Schonberg Index to predict LE has not been validated using electronic health data or been applied to populations outside the United States or in a prospective clinical setting. We used several proxies for subjective items, which may have caused a bias, but agreement between our findings and those in different U.S. populations strengthen our confidence. Furthermore, our sensitivity analyses supported our conclusions and minimize the possibility that these proxy substitutions markedly influenced the overall study findings. The factors used to assess LE in this index have been found to be predictive of mortality in multiple studies, suggesting that individuals in our population with functional and mobility limitations and comorbidities have a shorter LE than those without these conditions. 22, 23 We did not have data on whether the tests were conducted for screening or diagnostic purposes, but it is recommended to use FOBT only for screening, and it is unlikely to be used for diagnostic purposes. A previous study that was able to distinguish between diagnostic and screening mammograms found that only approximately 15% of all mammograms were diagnostic. 9 
Implications for Practice
Our findings suggest that national cancer screening policies could use predicted LE in addition to age to reduce overscreening older adults with limited LE. In addition, considering LE in cancer screening decisions may reduce underscreening of adults aged 75 and older with long predicted LE. Our modified version of the Schonberg Index capitalized on electronic data that were readily available from the CHS data warehouse. Indices that capitalize on electronic data are well suited for inclusion in individualized screening policies in countries with organized population-based screening programs. People with limited predicted LE should have their physicians evaluate potential benefits and harms of screening instead of receiving an automatic invitation for screening. Doing so might help older adults with short predicted LE avoid cancer screening tests with a long lag time to benefit that may only cause them harm. Figure 2 . Screening rates according to age and Schonberg score. Smaller proportions of people with shorter life expectancy (LE) were screened in all age groups, but differences were small. Fecal occult blood test (FOBT) and mammography rates in people aged 75 and older were generally much lower than in younger people, a trend that was not observed in prostate-specific antigen (PSA) tests. It is likely that the fact that the national screening program ends at the age of 75 mainly explains the lower rates of colorectal and breast cancer screening.
